You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

List of Excipients in Branded Drug METROGEL


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for Metrogel

Last updated: February 28, 2026

What is the excipient composition of Metrogel?

Metrogel (metronidazole topical gel) contains several excipients that support its delivery and stability. The key excipients include:

  • Carbomer 940: A thickening agent that provides gel consistency.
  • Glycerin: A humectant that retains moisture.
  • Sodium hydroxide: Used for pH adjustment.
  • Purified water: Solvent base.

Total excipient content usually comprises less than 10% of the formulation, concentrated mainly on carbomer and glycerin.

How does excipient choice impact formulation stability and patient compliance?

Excipient selection influences the physical stability, shelf life, and user experience:

  • Carbomer 940 provides a smooth, non-greasy texture that facilitates topical application.
  • Glycerin improves skin softness and prevents drying, enhancing patient adherence.
  • pH control via sodium hydroxide maintains chemical stability of metronidazole and minimizes irritation.

Changes in excipients can modify the gel’s viscosity, absorption, and sensory attributes, affecting both stability and compliance.

What are the commercial opportunities derived from excipient strategies?

The pharmaceutical industry is exploring innovations in excipients to optimize Metrogel and develop value-added products:

1. Formulation improvements

  • Developing lower-viscosity variants for ease of spread.
  • Incorporating skin-penetration enhancers compatible with existing excipients to increase efficacy.
  • Creating preservative-free or reduced-preservative versions for sensitive skin.

2. Biosimilar and generic products

  • Entry into markets with simplified excipient profiles offers cost reductions.
  • Focus on excipients with well-known safety profiles to expedite regulatory approval.

3. Combination products

  • Incorporating moisturizers or anti-inflammatory agents using compatible excipients.
  • Developing fixed-dose combinations to treat co-morbid skin conditions.

4. Novel excipient platforms

  • Using smart polymers responsive to skin conditions to improve controlled release.
  • Employing biodegradable or plant-based excipients to appeal to eco-conscious consumers.

5. Formulation patenting opportunities

  • Securing patents on novel excipient blends that enhance stability or efficacy.
  • Exploiting excipient strategies to extend market exclusivity.

What are the regulatory considerations for excipient modifications?

Regulatory agencies such as the FDA and EMA emphasize excipient safety, especially for topical formulations. New excipients or significant modifications require:

  • Demonstration of safety data.
  • Compatibility testing with the active pharmaceutical ingredient.
  • Stability studies.
  • Well-defined manufacturing processes and quality control measures.

FDA’s Inactive Ingredients Database assists in confirming excipient approval status and permissible concentrations [1].

How do excipient trends influence market entry and growth?

Innovations in excipients can:

  • Reduce manufacturing costs through simplified or scalable processes.
  • Improve product stability and shelf life, reducing wastage.
  • Enable formulation differentiation, driving brand preference.
  • Meet regulatory expectations for safety and sustainability.
  • Cater to niche markets such as organic or preservative-free products.

Summary of Key Opportunities

Opportunity Description
Formulation innovation Improved texture, efficacy, and patient adherence
Market expansion Entry into biosimilars and generics with optimized excipients
Product differentiation Fixed-dose combinations and eco-friendly formulations
Proprietary excipient blends Patent filings for novel excipient compositions
Regulatory compliance Ensuring safety and compatibility for new excipients

Key Takeaways

  • Excipient selection directly influences Metrogel’s stability, patient acceptability, and formulation scalability.
  • Innovations in excipients can lead to cheaper, more effective, and differentiated products.
  • Regulatory acceptance hinges on proven safety profiles and compatibility data.
  • Market expansion relies on tailored excipient strategies, particularly for biosimilars and combination therapies.
  • Environmental and safety considerations are increasingly shaping excipient development and commercialization.

FAQs

What excipients are most critical in topical gel formulations like Metrogel?
Carbomer 940 for viscosity, glycerin for moisture retention, sodium hydroxide for pH adjustment, and purified water as the base.

Can excipient modifications extend Metrogel's patent life?
Yes, developing novel excipient blends can support patent applications that extend market exclusivity.

Are there ongoing innovations in excipients for topical antibiotics?
Yes, research focuses on biodegradable, plant-based, and smart polymers to improve stability and patient outcomes.

How do excipients affect the regulatory approval process?
Regulators require safety data, stability information, and compatibility testing for any new or modified excipient.

What market segments could benefit from excipient innovation in Metrogel?
Generic manufacturers, biosimilar producers, and companies developing combination therapies or eco-friendly products.


References

[1] U.S. Food and Drug Administration. (2023). Inactive Ingredients Database. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/inactive-ingredients-database

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.